Skip to main content
. 2016 Sep 20;7(43):70589–70600. doi: 10.18632/oncotarget.12130

Table 1. Clinical and Molecular data of Cancers.

BRAF mutant/MSI BRAF mutant/MSS BRAF wild type /MSS p value P ValueA P ValueB P ValueC
RBWH cancers:
n 54 33 79 - - - -
Average age (yrs) 74.6 68.4 68.2 0.005 0.026 0.003 0.900
Female gender 42/54 (77.8%) 17/33 (51.5%) 33/79 (18.4%) 0.0002 0.017 <0.0001 0.407
Proximal site 41/43 (95.3%) 17/24 (70.8%) 15/63 (23.8%) <0.0001 0.008 <0.0001 0.0001
CIMP high 54/54 (100%) 32/33 (96.7%) 12/79 (15.1%) <0.0001 0.379 <0.0001 <0.0001
Envoi cancers:
n 63 37 44 - - - -
Average age (yrs) 77.9 72.6 63.6 <0.0001 0.01 <0.0001 0.004
Female gender 37/57 (64.9%) 26/37 (70.2%) 13/28 (46.4%) 0.12 0.66 0.16 0.07
Proximal site 53/57 (93.0%) 30/37 (81.1%) 9/28 (32.1%) <0.0001 0.10 <0.0001 <0.0001
CIMP high 59/63 (93.7%) 23/35 (65.7%) 0/35 (0%) <0.0001 0.001 <0.0001 <0.0001
A

P Value: P value between BRAF mutant/MSI and BRAF mutant/MSS cohorts;

B

P Value: P value between BRAF mutant/MSI and BRAF wild type cohorts;

C

P Value: P value between BRAF mutant/MSS and BRAF wild type cohorts